A Phase 1b/2a, Cross-over, Randomised, Double-blind, Placebo Controlled Study to Investigate the Safety and Pharmacodynamic Effects of GET 73 in Alcohol Dependent Subjects
Phase of Trial: Phase I/II
Latest Information Update: 11 Apr 2019
Price : $35 *
At a glance
- Drugs GET 73 (Primary)
- Indications Alcohol withdrawal
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Acronyms SPAD
- Sponsors CT Laboratories
- 29 Aug 2018 Status changed from recruiting to completed.
- 01 Sep 2017 Planned End Date changed from 1 Apr 2017 to 1 Nov 2017.
- 01 Sep 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Nov 2017.